Results for phase 2b trial of VLU therapy published
- Fri, 8/3/12 - 8:30am
- 0 Comments
- 857 reads
Healthpoint Biotherapeutics (Fort Worth, TX) announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published in The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue.
HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently under development for the treatment of venous leg ulcers.
The manuscript can be accessed online at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract.
For more information, visit www.Healthpointbio.com.